Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting
WESTPORT, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today announced the presentation of updates from its ongoing Phase 1/2 study of PORT-2 (IMM60), an invariant natural killer T cell (iNKT) agonist for patients with non-small cell lung cancer (NSCLC) and advanced melanoma, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022). The meeting is being held from November 8-12 in Boston, Massachusetts.
The poster includes updated data from the IMP-MEL study (currently being expanded in the U.S. and EU as the IMPORT-201 study), a multi-arm Phase 1/2 trial evaluating PORT-2 in multiple settings including front line and refractory NSCLC and refractory melanoma, both as a monotherapy and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). The data builds on previous results shared at the 2022 American Society of Clinical Oncology (ASCO) meeting in June.
“We are encouraged by the growing patient data set that supports the preliminary Phase 1 results showing that PORT-2 has a favorable safety and tolerability profile as a monotherapy at all doses tested to date,” said Dr. Ian Walters, Chief Executive Officer of Portage Biotech. “We continue to see single agent activity of PORT-2 at the 3 mg/m2 dose, which is the mid-dose level in our study. Based on the results so far, we are confident in the mechanistic potential of PORT-2 to activate both the adaptive and innate immune system and reduce the suppressive cells in the tumor microenvironment."
Dr. Walters continued, “Furthermore, in these patient populations that have failed multiple previous lines of treatment, it is essential that we provide new therapeutic options that could be administered as a monotherapy or complement other approaches. Having recently announced our clinical collaboration with Merck, we are pleased to have begun treating patients with PORT-2 in combination with pembrolizumab. PORT-2 has been shown to increase PD-L1 expression and thus has the potential for synergistic combination with checkpoint inhibitors and for the expansion of the use of anti-PD-1 therapy to an entirely new group of patients who do not currently respond to treatment. Interestingly, we observed a dose dependent increase in CD86+ B cells (which function as antigen presenting cells) inthe blood of patients following PORT-2, which has been associated with response to checkpoint inhibitors. We look forward to sharing further updates from the current study as well as progress in our randomized clinical trial evaluating PORT-2 as a monotherapy and in combination with pembrolizumab in the coming year.”
SITC presentations are available now to registrants through the conference platform. The PORT-2 poster will be added to the “Presentations & Publications” section of Portage’s website following the conference.
Category: Clinical Trials in Progress
About Portage Biotech Inc.
FOR MORE INFORMATION, PLEASE CONTACT:
Why NFTs Arenâ€™t Working Like They Should
IoT Evolution Solutions Theatre Presentation by Senzary
Taking Your MSP Business To New Heights With CPaaS